Precision Targeting of Misfolded Proteins

To view the webinar replay of “PRECISE-AD Phase 1b Blinded Interim Data Analysis"  Click Here

Working to Transform the Lives of People with Neurodegenerative Diseases

Working to Transform the Lives of People with Neurodegenerative Diseases

Learn about the ProMIS mission and our team

About Our Company

Leveraging Our Proprietary Platform to Target Critical Drivers of Disease

Leveraging Our Proprietary Platform to Target Critical Drivers of Disease

Explore how we’re applying our EpiSelect™ Platform

Explore Our Platform

Advancing Next-Generation Therapies and Vaccines Designed to Maximize Selectivity

Advancing Next-Generation Therapies and Vaccines Designed to Maximize Selectivity

Read about our pipeline of innovative candidates

View Product Pipeline

Latest News

View All News

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

View Press Release

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

View Press Release

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

View Press Release
View All News